SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as the community discusses potential catalysts stemming from activity surrounding the White House's social media, drawing comparisons to the stock's previous surges. Community members are debating the potential impact of this activity and its implications for a possible short squeeze. The stock's movement is also being compared to other meme stocks like BYND, with some suggesting a rotation of interest.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to recent revenue growth and speculation around a potential crypto treasury strategy, sparking significant after-hours volatility. The community is actively debating the stock's low float and potential for a short squeeze, with some cautioning against chasing the spike. Discussions also include the company's compliance status and potential catalysts for further upward movement.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings and potential catalysts like rate cuts and S&P 500 inclusion. The community is closely watching for a breakout above the $30 resistance level, with many expecting a significant move post-earnings. Bullish sentiment is fueled by strong growth metrics and the company's position as a disruptor in the fintech sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid discussions about potential trade deals with China and the ongoing government shutdown, with some questioning the timing of events. Community members are debating the implications of these factors on the stock and the broader market, while some highlight Trump's crypto holdings. Political commentary and comparisons to historical figures are also prevalent in the conversation.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending amid rumors of a potential acquisition by Novartis ($NVS), sending the stock soaring. The community speculates on the deal's likelihood and potential value, while noting positive clinical data and a strengthened pipeline. Discussions also involve the impact on the broader RNA therapeutics sector and comparisons to other companies in the space.

ETHZilla Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.

ETHZilla Corp

ETHZilla Corporation

ETHZilla Corporation is trending as investors discuss its potential undervaluation due to significant ETH holdings and cash reserves, with some highlighting Peter Thiel's investment as a bullish signal. Community members are actively debating its relation to the price of ETH and the possible influence of meme stock trends on its future performance, while others express concern about potential dilution from convertible notes.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle ($CRCL) is trending due to a mix of bullish sentiment and unusual options activity, specifically large volumes of out-of-the-money calls expiring in November, leading to speculation about a potential short squeeze or upcoming news. Community members are actively discussing breakout potential, key price levels, and the impact of a potential lockup expiry, with some eyeing ambitious price targets. Recent analyst ratings and broader trends in the crypto and digital asset space also appear to be fueling the conversation.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending as investors react to news of Larvotto Resources rejecting its acquisition offer, with community discussions focusing on the deal's potential restructuring and the company's intrinsic value. Despite the setback, many express confidence in UAMY's fundamentals, citing existing contracts and potential government support amid increasing geopolitical tensions around critical mineral supply chains. The community is weighing the short-term bearish sentiment against the long-term potential of UAMY in the antimony market.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is trending due to the FDA's correction confirming VOQUEZNA's market exclusivity through 2032, driving optimism about the drug's long-term potential. The community is also discussing the upcoming earnings report and potential for a short squeeze, given the high short interest. Bullish sentiment is fueled by strong analyst ratings and the drug's superior profile compared to existing GERD treatments.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals (BCRX) is trending amid discussions around its strategic acquisition of Astria Therapeutics to bolster its hereditary angioedema (HAE) portfolio, although some investors express concern about the deal's financial implications and dilution. Community talking points include the potential of navenibart, Astria's late-stage drug, and its impact on the competitive landscape, while others question management's decision-making and the company's future growth trajectory. Analysts have weighed in with revised price targets, adding to the ongoing conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PROF I&#39;m inclined to give the benefit of the doubt on the pipeline. After all, management has been asked about the new installs &#39;pipeline&#39; on just about every call for some years now, and has NEVER agreed to say what it was. In sharp contrast to that, the pipeline was here delivered as a veritable cold open. So I can&#39;t imagine those numbers aren&#39;t to some extent true. What really concerned me, is that the recurring revenue was up only 7% quarter over quarter. Aside from any issues on the pipeline, there are 60 installed sites and those sites need to be growing their business by more than 7% per year. What happened? None of the analysts asked.

Jacob cohen

John Rhett

StockTwits Web

Profound Medical Corp

 I'm inclined to give the benefit of the doubt on the pipeline. After all, management has been asked about the new installs 'pipeline' on just about every call for some years now, and has NEVER agreed to say what it was. In sharp contrast to that, the pipeline was here delivered as a veritable cold open. So I can't imagine those numbers aren't to some extent true. What really concerned me, is that the recurring revenue was up only 7% quarter over quarter. Aside from any issues on the pipeline, there are 60 installed sites and those sites need to be growing their business by more than 7% per year. What happened? None of the analysts asked.

John Tarlick

@johntarlick  
Wow.  What a wild trading session.  
I was real worried about Earnings, and sold out, prior. As a rule, Earnings for PROF are poor. And they were, again.  
But today I bought back in, and I threw just about everything I could get my hands on, too.  
There&#39;s a reason I did so, and it appears the smart money saw what I saw. 
And that is, in my best estimates, this coming quarter is the start of the turn around. What a huge gift this price collapse was!

  
Wow.  What a wild trading session.  
I was real worried about Earnings, and sold out, prior. As a rule, Earnings for PROF are poor. And they were, again.  
But today I bought back in, and I threw just about everything I could get my hands on, too.  
There's a reason I did so, and it appears the smart money saw what I saw. 
And that is, in my best estimates, this coming quarter is the start of the turn around. What a huge gift this price collapse was!

@QES There&#39;s no question it was oversold on the friday session. One good quarter after several years of under performing will blow the lid off. I did sense a bit of frustration on the part of the CCO, like he&#39;s doing everything he can but the sales contracts are just slow slow slow to close, each and every one.

 There's no question it was oversold on the friday session. One good quarter after several years of under performing will blow the lid off. I did sense a bit of frustration on the part of the CCO, like he's doing everything he can but the sales contracts are just slow slow slow to close, each and every one.

@johntarlick  
See https://www.linkedin.com/feed/update/urn:li:activity:7359207948335685633/Laurie  
Vertuccio with &quot;Viewpoint with Dennis Quaid&quot;.  PROF will gain access to both a long-form educational segment and professionally produced commercials for use in awareness campaigns and advertising.  
 
They need that desperately, as nobody knows about the TULSA option.  
 
Bullet #2 from earnings: &#39;qualified sales pipeline is also growing, and now stands at 80 new systems being classified within one of the “Verify, Negotiate and Contracting” stages.&#39;  That&#39;s a big deal.  
 
Website sucks, though. Pretend you are a patient looking for a center. It&#39;s not up-to-date. And the part to help you find a nearby center doesn&#39;t even work! I recently sent her a message about it. 
 
At least Vertuccio is aiming at awareness. The company&#39;s been failing at getting the word out to the public.  
 
I&#39;m betting on this turn-around, coming up from the bottom, essentially. To me, like I said, it was a gift. I accepted it, LOL.

Linkedin

  
Vertuccio with "Viewpoint with Dennis Quaid".  PROF will gain access to both a long-form educational segment and professionally produced commercials for use in awareness campaigns and advertising.  
 
They need that desperately, as nobody knows about the TULSA option.  
 
Bullet #2 from earnings: 'qualified sales pipeline is also growing, and now stands at 80 new systems being classified within one of the “Verify, Negotiate and Contracting” stages.'  That's a big deal.  
 
Website sucks, though. Pretend you are a patient looking for a center. It's not up-to-date. And the part to help you find a nearby center doesn't even work! I recently sent her a message about it. 
 
At least Vertuccio is aiming at awareness. The company's been failing at getting the word out to the public.  
 
I'm betting on this turn-around, coming up from the bottom, essentially. To me, like I said, it was a gift. I accepted it, LOL.